Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 1015550

Drug Profile

BI 1015550

Alternative Names: BI-1015550

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class 2 ring heterocyclic compounds; Alcohols; Amines; Anti-inflammatories; Antifibrotics; Chlorinated hydrocarbons; Cyclobutanes; Piperidines; Pyrimidines; Small molecules; Thiophenes
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic pulmonary fibrosis; Interstitial lung diseases

Most Recent Events

  • 13 Feb 2024 Boehringer Ingelheim completes a pharmacokinetics phase I trial (In volunteers) in Japan (PO) (NCT06139302)
  • 12 Feb 2024 Boehringer Ingelheim plans a phase I pharmacokinetics trial for Idiopathic pulmonary fibrosis (PO) in June 2024 (NCT06241560)
  • 02 Feb 2024 Boehringer Ingelheim plans the phase III FIBRONEER™-ON open-label extension trial for Idiopathic pulmonary fibrosis (PO), in July 2024 (NCT06238622)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top